For help on how to get the results you want, see our search tips.
5 results
Categories
Human Remove Human filter
Medicine
Summaries of opinion Remove Summaries of opinion filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Conditional approval Remove Conditional approval filter
-
List item
Summary of opinion: Idefirix
imlifidase, opinion date: 25/06/2020, Positive, Last updated: 26/06/2020 -
List item
Summary of opinion: Crysvita
burosumab, opinion date: 23/07/2020, Positive, Last updated: 24/07/2020 -
List item
Summary of opinion: Ayvakyt
avapritinib, opinion date: 23/07/2020, Positive, Last updated: 24/07/2020 -
List item
Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin)
Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020 -
List item
Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa
Active substance: andexanet alfa, DHPC type: Safety signal, Last updated: 17/06/2020